To ensure that the 2 + 2 HC16-HCP variant shows comparable tumor-targeting to the two-in-one antibody HCP-LCE, cellular binding experiments were performed on EGFR/PD-L1 double positive A431 and A549 cells by flow cytometry. The gene discussed is EGFR; the disease is neoplasm.